Add BrightSurf on Google Email

New $3.1M NIH grant for University of Houston to study how ‘spongy heart’ disease develops — and whether it can be stopped

University of Houston researcher Mingfu Wu has received a $3.1 million NIH grant to investigate left ventricular noncompaction, a serious heart condition that can lead to heart failure and abnormal heart rhythms. The study aims to uncover a common mechanism behind different genetic causes of LVNC and potentially identify new targets fo...

Giant-nucleus cells are key markers for early-stage cancer, study shows

Researchers at Nagoya University have identified giant-nucleus cells as precancerous markers in the kidneys, which emerge in response to iron toxicity and BRCA1 mutations. These cells exhibit cancer-related gene activity and can signal early cancer development in surrounding tissue, with distinct biological profiles in BRCA1-mutant rats.

SourceNagoya University·JournalRedox Biology·TypeExperimental study·DateSep 11, 2026

PolyU research team develops trustworthy AI framework TRUECAM to enhance reliability of pathology AI in cancer diagnosis

The PolyU research team has developed TRUECAM, an integrated AI framework that ensures data and model trustworthiness in cancer diagnosis. The framework can assess the level of an AI's confidence in its diagnostic outputs and proactively prompts pathologists to review cases when uncertainty is high.

SourceThe Hong Kong Polytechnic University·JournalNature Biomedical Engineering·DateAug 20, 2026

PolyU develops AI-powered virtual patient simulation system integrating multimodal data to advance personalized cancer treatment

The PolyU developed AI Virtual Patient Simulation System combines multimodal data from genomic, medical imaging and clinical records to create a digital twin model tracking real-time changes in a patient's condition. It predicts the effectiveness of different cancer treatment options and supports personalized medical solutions.

SourceThe Hong Kong Polytechnic University·JournalMedical Image Analysis·DateAug 14, 2026

Can AI become a trusted assistant for pathologists?

The article highlights the need for AI tools to provide interpretable and reportable results, with a focus on improving turnaround time, diagnostic consistency, and clinical decision-making. While AI is unlikely to replace pathologists, it can help convert tissue morphology into actionable evidence for better patient care

SourceScience China Press·JournalScience Bulletin·DateJul 31, 2026

Association for Molecular Pathology recognizes UW physician–scientist for exceptional service to the field

Daniel E. Sabath, a professor at UW Department of Laboratory Medicine and Pathology, has won the Association for Molecular Pathology's 2026 Meritorious Service Award for his dedication and effort over three decades. He is being honored for his leadership roles, scientific expertise, and collaborative spirit in advancing education and s...

New neuroendocrine markers PITX2, PHOX2B, and HAND2 do not offer diagnostic utility in fine-needle aspiration biopsies of primary and secondary medullary thyroid carcinomas

A retrospective study found that PITX2, PHOX2B, and HAND2 do not offer diagnostic utility in fine-needle aspiration biopsies of primary and secondary medullary thyroid carcinomas. The markers were expressed in some samples but did not improve diagnosis accuracy.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Pathology·DateJun 29, 2026

Heterogeneous phenotype of acute leukemia with EWSR1 or FUS gene rearrangements

Acute leukemias with EWSR1 or FUS gene rearrangements display heterogeneous clinical and pathological characteristics. Cytogenetic karyotyping and fluorescence in situ hybridization remain crucial tools for detecting chromosomal translocations, while advanced molecular diagnostic methods are recommended to improve accurate diagnosis.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Pathology·DateJun 27, 2026

A lifecycle framework for digital pathology implementation: Integrating infrastructure, workflow, regulatory compliance, and ai readiness for sustainable adoption

A lifecycle framework helps laboratories overcome barriers to digital pathology adoption by integrating infrastructure, workflow redesign, validation, interoperability, and AI readiness. The framework addresses institutional governance, cybersecurity, education, and performance monitoring to ensure durable success.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Pathology·DateJun 27, 2026

Artificial intelligence in breast pathology: Recent advances in multimodal models, explainability, and clinical applications

The review discusses key AI concepts, including algorithms, models, architectures, machine learning, deep learning, and multimodal models. It highlights their clinical applications, such as detection of lymph node metastases, Nottingham grading, biomarker quantification, risk stratification, and prognostic prediction.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Pathology·DateJun 26, 2026

New framework renders AI trustworthy for cancer subtyping

Researchers have developed a versatile uncertainty-aware AI framework called TRUECAM that provides customizable accuracy guarantees for cancer subtype classifications. TRUECAM outperforms existing approaches to digital pathology AI uncertainty quantification, detecting out-of-scope inputs and improving fairness across sex and race.

SourceVanderbilt University Medical Center·JournalNature Biomedical Engineering·TypeData/statistical analysis·DateJun 23, 2026

Mount Sinai researchers identify RNA biomarkers that could offer a simple blood test for earlier Alzheimer’s diagnosis

Researchers discovered blood RNA biomarkers that could support earlier diagnosis of Alzheimer's disease, potentially reducing the need for invasive tests. They identified brain-specific markers in circulating blood nanoparticles, which may offer a minimally invasive approach for diagnosing the progressive neurodegenerative disease.

Alexander Kerr named recipient of the 2026 IADR Distinguished Scientist Award in Oral Medicine & Pathology Research

Alexander Kerr, NYU Clinical Professor, recognized for outstanding research on oral cavity squamous cell carcinoma and oral potentially malignant disorders. The IADR Distinguished Scientist Award is one of the highest honors bestowed by IADR, recognizing contributions to understanding oral health and disease mechanisms.

From pathology image to biological discovery: A journey with LazySlide

LazySlide enables systematic whole-slide image analysis using AI models and links visual patterns to text concepts. The study demonstrates its potential in analyzing tissue samples, identifying biological pathways, and reducing the barrier for applying advanced image analysis methods.

The cost of survival: Women more likely to survive cancer but suffer more severe side effects

A recent study found that women have a 21% lower risk of death compared to men, but a 12% higher risk of severe side effects from cancer treatment. The research, conducted in partnership with international collaborators, analyzed data from over 20,000 cancer patients and identified sex-based differences in survival and treatment toxicity.

SourceAdelaide University·JournalJNCI Journal of the National Cancer Institute·TypeMeta-analysis·DateMar 15, 2026

Rare pancreatic tumor case suggests distinctive calcification patterns in solid pseudopapillary neoplasms

A new case report describes a large, calcified solid pseudopapillary neoplasm of the pancreatic head, emphasizing the importance of multidisciplinary evaluation and long-term follow-up for monitoring recurrence. The case underscores the diagnostic value of integrating imaging, histopathology, and immunohistochemistry.

SourceImpact Journals LLC·JournalOncoscience·TypeCase study·DateMar 6, 2026